Short answer: yes. Spravato (esketamine) is covered by most major insurers in Maryland — including CareFirst BlueCross BlueShield, Aetna, Cigna, UnitedHealthcare, and Kaiser Permanente — as well as Maryland Medicaid (HealthChoice) and Medicare Part B, when it is prescribed for treatment-resistant depression and your plan’s medical-necessity criteria are met. Because Spravato is FDA-approved, it is treated very differently from off-label ketamine infusions, which most plans will not pay for.
This guide explains exactly how coverage works for Maryland patients: who qualifies, which insurers cover it, how prior authorization and appeals work, a Maryland step-therapy protection most people don’t know about, and how to bring your out-of-pocket cost down. If you want the actual dollar figures, see our companion guide on how much Spravato costs — this article focuses on coverage and approval.
Why Spravato Is Usually Covered (When IV Ketamine Isn’t)
The single most important fact about Spravato coverage is that the medication is FDA-approved. The FDA approved Spravato in 2019 for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. In January 2025, the FDA went a step further and approved Spravato as the first standalone (monotherapy) treatment for treatment-resistant depression — meaning it no longer has to be paired with an oral antidepressant, though many patients still use both together.
FDA approval is why insurers cover it. Carriers routinely pay for on-label, clinically proven medications, especially for a condition where other treatments have already failed. This is also why Spravato is handled so differently from IV and IM ketamine: those are used off-label for depression, are generally considered experimental by insurers, and are usually paid out of pocket. Spravato sits in the rare category of a rapid-acting depression treatment that insurance will actually fund.
Do You Qualify? Spravato Coverage Criteria
Coverage is not automatic — your plan will want documentation that Spravato is medically necessary for you. Across nearly every Maryland insurer, the criteria look the same:
- A treatment-resistant depression diagnosis. You generally need to have tried at least two different antidepressants, from different drug classes, at adequate doses for a sufficient period (often 6–8 weeks each) without adequate relief. Not sure if you qualify? Our guide on how to know if you have treatment-resistant depression walks through the definition.
- Documented severity. Many plans (CareFirst included) want your depression severity confirmed with a standardized rating scale such as the PHQ-9, MADRS, or HDRS, verified by a psychiatrist.
- Treatment at a REMS-certified clinic. Spravato can only be given in a clinic certified under the FDA’s Risk Evaluation and Mitigation Strategy program, where you are monitored for at least two hours after each dose. Insurers require this certified setting for coverage. Here’s how the Spravato REMS program works.
- You’re 18 or older with no contraindications (such as certain blood-pressure, vascular, or aneurysm-history concerns) that your provider rules out during evaluation.
One thing worth flagging: because of the 2025 monotherapy approval, you may no longer be required to stay on an oral antidepressant to get Spravato covered. Payer policies are still catching up, so confirm your specific plan’s current requirement.
Which Maryland Insurers Cover Spravato?
Most major commercial carriers operating in Maryland include Spravato in their formularies for treatment-resistant depression, each with its own prior-authorization rules:
|
Insurer |
Covers Spravato for TRD? |
Notes |
|---|---|---|
|
CareFirst BlueCross BlueShield |
Yes |
Largest Maryland carrier; prior auth via CVS Caremark specialty guidelines |
|
Aetna |
Yes |
Prior authorization required |
|
Cigna |
Yes |
Prior authorization required |
|
UnitedHealthcare |
Yes |
Prior authorization required |
|
Kaiser Permanente |
Yes |
Coverage through Kaiser network providers |
|
Medicare Part B |
Yes |
Covered as an in-office treatment |
|
Maryland Medicaid (HealthChoice) |
Yes |
Through your managed care organization; low to no cost |
As an example of how detailed these policies get: CareFirst — the dominant insurer across Maryland, DC, and Northern Virginia — administers its Spravato criteria through CVS Caremark’s specialty guideline management. CareFirst generally requires a confirmed diagnosis of severe major depressive disorder documented with a rating scale and verified by a psychiatrist, the patient to be 18 or older, and trials of two antidepressants from two different classes, each used at the maximally tolerated labeled dose for at least eight weeks in the current episode, plus an inadequate response to an augmentation trial or cognitive behavioral therapy. Other carriers use similar — but not identical — checklists, which is why verifying your specific plan matters.
Medicare and Spravato in Maryland (Part B)
Because Spravato is administered in a clinic by a provider rather than picked up at a pharmacy, Medicare covers it under Part B (medical), not Part D (prescription drugs). In 2026 you first meet the $283 annual Part B deductible; after that, Medicare pays 80% of the approved amount and you’re responsible for the remaining 20% coinsurance. A Medigap (supplement) or Medicare Advantage plan can reduce or eliminate that coinsurance. If you’re comparing covered options, you may also want to read whether Medicare covers TMS therapy.
Important: patients on Medicare, Medicaid, or any government insurance are not eligible for the manufacturer’s $10 commercial copay card (federal rules prohibit it). Those patients should ask about the Patient Assistance Program instead, covered below.
Maryland Medicaid (HealthChoice) Coverage
Maryland Medicaid covers Spravato for treatment-resistant depression through the HealthChoice program. Maryland HealthChoice is delivered by nine managed care organizations (MCOs): Aetna Better Health, CareFirst Community Health Plan Maryland, Jai Medical Systems, Kaiser Permanente, Maryland Physicians Care, MedStar Family Choice, Priority Partners, UnitedHealthcare Community Plan, and Wellpoint Maryland.
For Medicaid patients, out-of-pocket costs are typically very low to $0. Each MCO can set its own prior-authorization and documentation requirements, so the approval paperwork still has to be completed — but the cost barrier is usually minimal. If you’re enrolled in HealthChoice, check with your specific MCO (or ask your clinic to verify) before your first session.
Medical Benefit vs. Pharmacy Benefit — Why It Matters
Spravato can fall under either your medical benefit or your pharmacy benefit, depending on how your plan is structured — and this affects what you pay. Under the medical benefit, the drug and the in-office monitoring are often billed together as part of the visit. Under the pharmacy benefit, the medication may be treated as a specialty drug with its own copay tier, billed separately from the monitoring visit. When you call your insurer, ask specifically: “Is Spravato covered under my medical or pharmacy benefit, and what’s my cost-share under each?” Relay that answer to your clinic so billing is set up correctly the first time.
How Prior Authorization Works (Step by Step)
Nearly every Maryland plan requires prior authorization before Spravato is approved. Here’s the typical path:
- Evaluation at a certified provider. A psychiatrist confirms your diagnosis and that you meet treatment-resistant depression criteria.
- Documentation is gathered. Your provider compiles your diagnosis, the antidepressants you’ve tried, doses and durations, and the medical justification for Spravato.
- The request is submitted. The clinic sends the prior-authorization package to your insurer (or its pharmacy benefit manager).
- Coverage determination. Most decisions come back within 1–3 weeks. If approved, the insurer outlines your copay/coinsurance and any session limits.
- Treatment begins. Once authorized, you schedule your first dose at the REMS-certified clinic.
A good clinic handles this paperwork for you — at Bright Horizons Psychiatry, we manage the prior authorization and verify your benefits before your first dose, so you know what to expect.
A Maryland Protection Most Patients Don’t Know About
Maryland law limits “step therapy” — the practice of forcing patients to “fail first” on cheaper drugs before a carrier approves the one their doctor recommends. Under the Maryland Insurance Article’s step-therapy provisions, commercial carriers must offer a clear exception process, and they generally cannot require you to try a medication that is not FDA-approved for your condition as a precondition for coverage. Because Spravato is FDA-approved specifically for treatment-resistant depression, your prescriber can request a step-therapy exception rather than cycling through additional medications that aren’t indicated for TRD. This is a useful lever if a carrier pushes back, and an experienced psychiatry practice will know how to invoke it. (This applies to state-regulated commercial plans; self-funded employer plans and government programs follow their own rules.)
What If Your Insurance Denies Spravato?
A denial is rarely the final word. Initial denials usually come down to a few fixable issues: insufficient documentation of prior antidepressant failures, a missing or incomplete prior authorization, or the request being read as “not medically necessary.” The fix is almost always more documentation, not a different treatment.
The appeal process typically involves a formal appeal letter, additional medical records, a letter of medical necessity from your psychiatrist, and — if needed — a peer-to-peer review where your doctor speaks directly with the insurer’s medical reviewer. A meaningful share of initial denials are overturned on appeal when the paperwork is complete, so it’s worth pushing. Your clinic should lead this process on your behalf.
Lowering Your Out-of-Pocket Cost
Even with coverage, deductibles and copays can sting — especially early in the calendar year. Several programs can help:
- SPRAVATO withMe Savings Program. For patients with commercial/private insurance, this can bring the medication cost down to as little as $10 per treatment, up to $8,150 in assistance per calendar year. It covers the medication, not the monitoring fee (a separate rebate can help there). Not available to Medicare/Medicaid patients.
- Patient Assistance Program. For uninsured or underinsured patients who meet income criteria, the manufacturer’s program may provide the medication at no cost.
- HSA/FSA dollars. Spravato copays and coinsurance are eligible expenses you can pay with pre-tax health-savings or flexible-spending accounts.
For the full breakdown of per-session, first-month, and maintenance numbers with and without insurance, see our Spravato cost guide.
How Bright Horizons Psychiatry Handles Insurance
Bright Horizons Psychiatry is a REMS-certified Spravato provider with offices in Rockville and Frederick, Maryland. Our team verifies your benefits, confirms whether Spravato falls under your medical or pharmacy benefit, files the prior authorization, and — if a denial comes back — manages the appeal, including peer-to-peer review. You can review the plans we work with on our insurance and billing page, and learn what treatment itself is like in our guide to Spravato side effects and what to expect.
Want to know your actual coverage and cost? Contact our team for a benefits check and we’ll walk you through your plan, the savings programs, and your treatment schedule before you commit to anything.
Frequently Asked Questions
Is Spravato covered by insurance in Maryland?
Yes. Most major Maryland insurers — including CareFirst BlueCross BlueShield, Aetna, Cigna, UnitedHealthcare, and Kaiser Permanente — plus Maryland Medicaid (HealthChoice) and Medicare Part B cover Spravato for treatment-resistant depression when medical-necessity criteria are met and prior authorization is approved.
Does Maryland Medicaid cover Spravato?
Yes. Maryland Medicaid covers Spravato for treatment-resistant depression through the HealthChoice program and its nine managed care organizations. Out-of-pocket costs are typically very low to $0, though each MCO sets its own prior-authorization requirements.
Does Medicare cover Spravato?
Yes, under Medicare Part B, because Spravato is administered in-office. In 2026 you meet the $283 Part B deductible, then Medicare pays 80% and you owe 20% coinsurance. A Medigap or Medicare Advantage plan can reduce that share. Medicare patients are not eligible for the manufacturer’s commercial copay card.
How long does Spravato prior authorization take?
Most prior-authorization decisions come back within 1 to 3 weeks. Urgent cases can sometimes be expedited. A complete, well-documented request avoids delays, which is why most patients let their clinic handle the paperwork.
Do I still have to take an antidepressant with Spravato?
Not necessarily. In January 2025 the FDA approved Spravato as a standalone (monotherapy) treatment for treatment-resistant depression, so it no longer must be paired with an oral antidepressant. Many patients still use both, and some insurer policies are still catching up, so confirm your plan’s current requirement.
What if my insurance denies Spravato?
Denials are usually fixable. Most stem from incomplete documentation of prior antidepressant trials. Your psychiatrist can appeal with additional records, a letter of medical necessity, and a peer-to-peer review. Many initial denials are overturned when the paperwork is complete.
This article is for general informational purposes and reflects 2026 coverage rules; it is not medical, legal, or insurance advice. Coverage, criteria, and costs vary by plan and individual circumstances. Reviewed by Dr. Amir Etesam, Bright Horizons Psychiatry. Please verify benefits with your insurer and clinic before beginning treatment.
